Locally advanced cervix cancer is a major health problem in resource-limited areas of the world. Brachytherapy following pelvic chemoradiation is challenging, as large irregular clinical target volumes need adequate dose delivery while respecting limits of normal tissue tolerance. Achieving this is practically impossible using intracavitary brachytherapy alone. Consequently, combined intracavitary and interstitial brachytherapy provides higher chances of local control.